Cargando…
A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients
We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spik...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695068/ https://www.ncbi.nlm.nih.gov/pubmed/36366338 http://dx.doi.org/10.3390/vaccines10111830 |
_version_ | 1784837964719718400 |
---|---|
author | Watanabe, Marika Yakushijin, Kimikazu Funakoshi, Yohei Ohji, Goh Ichikawa, Hiroya Sakai, Hironori Hojo, Wataru Saeki, Miki Hirakawa, Yuri Matsumoto, Sakuya Sakai, Rina Nagao, Shigeki Kitao, Akihito Miyata, Yoshiharu Koyama, Taiji Saito, Yasuyuki Kawamoto, Shinichiro Yamamoto, Katsuya Ito, Mitsuhiro Murayama, Tohru Matsuoka, Hiroshi Minami, Hironobu |
author_facet | Watanabe, Marika Yakushijin, Kimikazu Funakoshi, Yohei Ohji, Goh Ichikawa, Hiroya Sakai, Hironori Hojo, Wataru Saeki, Miki Hirakawa, Yuri Matsumoto, Sakuya Sakai, Rina Nagao, Shigeki Kitao, Akihito Miyata, Yoshiharu Koyama, Taiji Saito, Yasuyuki Kawamoto, Shinichiro Yamamoto, Katsuya Ito, Mitsuhiro Murayama, Tohru Matsuoka, Hiroshi Minami, Hironobu |
author_sort | Watanabe, Marika |
collection | PubMed |
description | We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spike protein were measured using the QuaResearch COVID-19 Human IgM IgG ELISA kit. The previous study included 25 allogeneic HSCT patients who received two doses of BNT162b2. Following the exclusion of three patients because of the development of COVID-19 (n = 2) and loss to follow-up (n = 1), the study evaluated 22 allogeneic HSCT patients who received a third dose of COVID-19 mRNA vaccine (BNT162b2 [n = 15] and mRNA-1273 [n = 7]). Median age at the time of the first vaccination was 56 (range, 23–71) years. Five patients were receiving immunosuppressants at the third vaccination, namely calcineurin inhibitors (CI) alone (n = 1), steroids alone (n = 2), or CI combined with steroids (n = 2). Twenty-one patients (95%) seroconverted after the third dose. None of our patients had serious adverse events, new-onset graft-versus-host disease (GVHD), or GVHD exacerbation after vaccination. A third dose of the BNT162b2 and mRNA-1273 COVID-19 vaccines was safe and effective for allogeneic HSCT patients. |
format | Online Article Text |
id | pubmed-9695068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96950682022-11-26 A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients Watanabe, Marika Yakushijin, Kimikazu Funakoshi, Yohei Ohji, Goh Ichikawa, Hiroya Sakai, Hironori Hojo, Wataru Saeki, Miki Hirakawa, Yuri Matsumoto, Sakuya Sakai, Rina Nagao, Shigeki Kitao, Akihito Miyata, Yoshiharu Koyama, Taiji Saito, Yasuyuki Kawamoto, Shinichiro Yamamoto, Katsuya Ito, Mitsuhiro Murayama, Tohru Matsuoka, Hiroshi Minami, Hironobu Vaccines (Basel) Brief Report We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spike protein were measured using the QuaResearch COVID-19 Human IgM IgG ELISA kit. The previous study included 25 allogeneic HSCT patients who received two doses of BNT162b2. Following the exclusion of three patients because of the development of COVID-19 (n = 2) and loss to follow-up (n = 1), the study evaluated 22 allogeneic HSCT patients who received a third dose of COVID-19 mRNA vaccine (BNT162b2 [n = 15] and mRNA-1273 [n = 7]). Median age at the time of the first vaccination was 56 (range, 23–71) years. Five patients were receiving immunosuppressants at the third vaccination, namely calcineurin inhibitors (CI) alone (n = 1), steroids alone (n = 2), or CI combined with steroids (n = 2). Twenty-one patients (95%) seroconverted after the third dose. None of our patients had serious adverse events, new-onset graft-versus-host disease (GVHD), or GVHD exacerbation after vaccination. A third dose of the BNT162b2 and mRNA-1273 COVID-19 vaccines was safe and effective for allogeneic HSCT patients. MDPI 2022-10-29 /pmc/articles/PMC9695068/ /pubmed/36366338 http://dx.doi.org/10.3390/vaccines10111830 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Watanabe, Marika Yakushijin, Kimikazu Funakoshi, Yohei Ohji, Goh Ichikawa, Hiroya Sakai, Hironori Hojo, Wataru Saeki, Miki Hirakawa, Yuri Matsumoto, Sakuya Sakai, Rina Nagao, Shigeki Kitao, Akihito Miyata, Yoshiharu Koyama, Taiji Saito, Yasuyuki Kawamoto, Shinichiro Yamamoto, Katsuya Ito, Mitsuhiro Murayama, Tohru Matsuoka, Hiroshi Minami, Hironobu A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients |
title | A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients |
title_full | A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients |
title_fullStr | A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients |
title_full_unstemmed | A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients |
title_short | A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients |
title_sort | third dose covid-19 vaccination in allogeneic hematopoietic stem cell transplantation patients |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695068/ https://www.ncbi.nlm.nih.gov/pubmed/36366338 http://dx.doi.org/10.3390/vaccines10111830 |
work_keys_str_mv | AT watanabemarika athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT yakushijinkimikazu athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT funakoshiyohei athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT ohjigoh athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT ichikawahiroya athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT sakaihironori athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT hojowataru athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT saekimiki athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT hirakawayuri athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT matsumotosakuya athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT sakairina athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT nagaoshigeki athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT kitaoakihito athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT miyatayoshiharu athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT koyamataiji athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT saitoyasuyuki athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT kawamotoshinichiro athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT yamamotokatsuya athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT itomitsuhiro athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT murayamatohru athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT matsuokahiroshi athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT minamihironobu athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT watanabemarika thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT yakushijinkimikazu thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT funakoshiyohei thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT ohjigoh thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT ichikawahiroya thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT sakaihironori thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT hojowataru thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT saekimiki thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT hirakawayuri thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT matsumotosakuya thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT sakairina thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT nagaoshigeki thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT kitaoakihito thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT miyatayoshiharu thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT koyamataiji thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT saitoyasuyuki thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT kawamotoshinichiro thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT yamamotokatsuya thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT itomitsuhiro thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT murayamatohru thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT matsuokahiroshi thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT minamihironobu thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients |